Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
05:50pm, Tuesday, 23'rd Jun 2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
10:00am, Thursday, 18'th Jun 2026
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to conta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
05:36pm, Tuesday, 16'th Jun 2026
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
10:00am, Thursday, 11'th Jun 2026
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contac
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
01:20pm, Tuesday, 09'th Jun 2026
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advise
U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
11:46am, Thursday, 04'th Jun 2026
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
08:02am, Thursday, 04'th Jun 2026
ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among treated patients, despite meeting its mai
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
10:51pm, Wednesday, 03'rd Jun 2026
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confir
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
02:49pm, Tuesday, 05'th May 2026
ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
10:23am, Monday, 04'th May 2026
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
09:35am, Monday, 04'th May 2026
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
07:30am, Monday, 04'th May 2026
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equiv
